Nanoplateletsomes for rapid hemostasis performance

Uncontrollable hemorrhage remains staple trouble in surgical procedures and a leading cause after major trauma. The bleeding issue may trigger various pathologic scenarios that can lead to tissue morbidities and mortalities, and currently available on-site hemostatic agents are confined to a narrow therapeutic index and may carry the risk of immunogenicity. Inspired by the crucial role of platelets in the process of thrombus, a platelet-mimetic plateletsome with wound targeting and blood coagulation properties is developed for hemorrhage control. Plateletsome is formulated by integrating platelet membranes with functionalized synthetic liposomes and exhibits superior wound targeting and effective hemostasis properties. It presents less blood loss and shorter hemostasis time than the platelet membrane vehicles or the conventional liposomes in the mouse tail transection model. The strong homing of the biomimetic plateletsome to the thrombus was also confirmed, demonstrating the potential of this engineered cell membrane vesicle as a biomimetic hemostat for bleeding treatment.